Feature | September 07, 2010| Dave Fornell

Devices, Coated Bandages Help Reduce Bleeding Complications

The first drug-coated vascular closure device is the Cardiva Catalyst III. Its protamine sulfate coating neutralizes heparin in the tissue adjacent to the device to facilitate quick vessel closure.

Following cath lab procedures, the final step is to attain hemostasis at the arteriotomy access site. Manual compression has been the gold standard for decades, but vascular closure devices (VCDs) can speed wound closure, and hemostatic pads can help decrease clotting times. VCDs and the new dressings also accelerate patient ambulation.

Manual compression advocates say it is less expensive than closure devices and does not leave behind foreign materials at the wound site. However, this method requires patients to sit on their backs in a hospital bed for hours, which requires additional nursing attention and may lead to additional patient discomfort.

Vascular Closure Devices
VCDs were developed in the 1990s to help control high rates of access site bleeding from compression alone. Despite improving patient outcomes, they have not been widely adopted, partly due to their higher cost as compared to compression. VCDs offer a means to improving patient comfort and decrease time to hemostasis. While vascular closure devices add costs to procedures, physicians who prefer them say the advantages include reduced nursing time and faster ambulation. Both of these factors also can help increase staff efficiency and patient throughput.

These devices offer various methods to seal the arteriotomy, including sutures, spring-clips and bioabsorbable plugs.

In 2001, about one-third of diagnostic and percutaneous coronary interventions (PCI) used a VCD. In 2006, more than 2 million VCDs were sold – about 1.6 million in the United States and 500,000 in Europe.(2)

Clinical Data Shows VCD Advantage
In 2007, a study of 12,937 patients showed fewer complications for those who received a VCD (2.4 percent) as opposed to compression alone (4.9 percent).(3)

A recent single center study of 428 patients, who received either an AngioSeal or Mynx VCD, showed similar complication rates as the 2007 study. The two devices also showed similarities in their complications, with a rate of 2.1 percent.(1) Hemostasis was achieved by the VCD followed by two to five minutes of manual pressure in all patients. Time to ambulation was two hours post-VCD placement, as compared to four hours with patients who had manual compression alone, researchers said.

Radial Compression Devices
Radial artery access through the wrist, as opposed to femoral access, is commonly used overseas. But in the United States, is usage is less than 10 percent. However, advocates of the wrist over the femoral artery are gaining numerous converts, because of the virtual elimination of bleeding complications and much faster patient ambulation. With an increasing number of radial access procedures being performed, several radial compression bracelet devices have entered the market.

Hemostatic Bandages
Several companies produce dressings that contain compounds that speed clotting and reduce the time to hemostasis. These products are generally used along with manual compression. These substances include marine organism-derived chitosan, calcium alginate from seaweed, mineral substances from clay and thrombin derived from animal sources.

The similarity of the chitosan compound used by two vendors led to a patent infringement case, which was resolved earlier this year. In April, a federal jury awarded Marine Polymer $29.4 million in its case against HemCon Medical Technologies. Both companies use a chitosan-based clotting compound in their wound dressings, but the sources of the material differ. Marine Polymer uses cultures of marine micro algae, while HemCon uses chitosan derived from shrimp shells.

Marine Polymer plans to seek accounting for HemCon’s sales in 2010 and seeks a permanent injunction to preclude further sales of HemCon’s products in the United States. HemCon has asked the U.S. Patent Office to re-examine, and possibly invalidate or limit, Marine Polymer’s patent in light of prior publications about chitosan before its patent was issued.

1. Shah Azmoon, et al. “Vascular Complications after Percutaneous Coronary Intervention Following Hemostasis with the Mynx Vascular Closure Device Versus the AngioSeal Vascular Closure Device.” Journal of Invasive Cardiology, vol. 22, issue 4, April 12, 2010, pages 175-178.

2. Harold L. Dauerman, et al. “Vascular Closure Devices: The Second Decade.” Journal of the American College of Cardiology, 2007, vol. 50, pages 1617-1626

3. Nipun Arora, et al. “A Propensity Analysis of the Risk of Vascular Complications After Cardiac Catheterization Procedures With the Use of Vascular Closure Devices.” American Heart Journal. 2007, vol.153, pages: 606-611.

Related Content

angioseal, angio-seal, terumo, St. Jude, vascular closure devices
News | Vascular Closure Devices| October 18, 2016
October 18, 2016 — Abbott and St. Jude Medical Inc.
Vivasure Medical, Closure Device, Series C financing
News | Vascular Closure Devices| September 12, 2016
September 12, 2016 — Vivasure Medical announced last week that the company has completed a Series C financing of €16.
nanoparticles, blood clotting, internal bleeding, American Chemical Society study, Erin B. Lavik

Nanoparticles (green) help form clots in an injured liver. The researchers added color to the scanning electron microscopy image after it was taken. Image courtesy of Erin Lavik, Ph.D.

News | Hemostasis Management| August 24, 2016
August 24, 2016 — Whether severe trauma occurs on the battlefield or the highway, saving lives often comes down to...
Rex medical, Closer Vascular Sealing System, VSS, vascular closure, bioresorbable vascular closure device

A close up view of the Rex Medical Closer Vascular Sealing System components.

Technology | Vascular Closure Devices| August 03, 2016
August 3, 2016 — The U.S.
Vivasure Medical, PerQSeal, vascular closure device, CE Mark
News | Vascular Closure Devices| January 18, 2016
Vivasure Medical announced Conformité Européenne (CE) Mark approval of the world’s first fully bioabsorbable...
News | Hemostasis Management| January 06, 2016
The Medicines Company announced Dec. 18 it has entered into a purchase agreement pursuant to which certain subsidiaries...
News | Vascular Closure Devices| December 16, 2015
Scientists at CBSET have presented preclinical evidence that the Manta Large Bore Vascular Closure Device (VCD) from...
platelet-like particles, PLPs, clotting, substitute, Carver, Lyon, NIBIB

Cartoon representation of a deformable platelet-like particle with fibrin nanobodies attached

Feature | Antiplatelet and Anticoagulation Therapies| July 13, 2015
Researchers have created tiny gel particles that can perform the same essential functions as platelets. The particles...
News | March 30, 2015
The Medicines Company announced that the European Commission has granted marketing authorization for two acute care...
Feature | March 02, 2015
Cardinal Health announced plans to acquire Johnson & Johnson’s Cordis business, a leading global manufacturer of...
Overlay Init